HK Stock Movement | IMMUNEONCO-B (01541) Rises Nearly 4% as IND Application for Self-Developed Amurelifusp-α Subcutaneous Formulation IMM0306S Accepted

Stock News12-19

IMMUNEONCO-B (01541) rose nearly 4%, reaching HK$6.23 by the time of writing, with a trading volume of HK$3.12 million. The company announced on December 18 that the Investigational New Drug (IND) application for its self-developed bispecific antibody-recombinant protein drug Amurelifusp-α (subcutaneous injection formulation, IMM0306S), targeting both CD47 and CD20 for the treatment of systemic lupus erythematosus (SLE), has been officially accepted by China's National Medical Products Administration (NMPA). This marks a significant milestone in the company's innovative drug development for autoimmune diseases.

IMM0306S is a subcutaneous formulation derived from IMMUNEONCO-B's core product, Amurelifusp-α (IMM0306). Amurelifusp-α (CD47xCD20, IMM0306) is the world's first CD47xCD20 bispecific molecule to enter clinical development, based on the company's proprietary "mAb-Trap" technology platform. The company has established a comprehensive development strategy for this product.

Notably, at the 67th American Society of Hematology (ASH) Annual Meeting, IMMUNEONCO-B presented Phase I/II clinical data for Amurelifusp-α (IMM0306) combined with lenalidomide in treating relapsed/refractory CD20-positive follicular lymphoma (R/R FL). The data showed an objective response rate (ORR) of 91.2% and a complete response rate (CR) of 67.6% in patients who had previously failed at least one line of anti-CD20 monoclonal antibody therapy. The combination demonstrated manageable safety with no risk of cytokine release syndrome. The ongoing Phase I/II study offers a promising new immunotherapy strategy for this currently incurable disease with limited treatment options post-relapse.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment